<DOC>
	<DOCNO>NCT01095991</DOCNO>
	<brief_summary>The purpose study evaluate effect AZD1656 Sitagliptin pharmacokinetics vice versa patient Type 2 Diabetes Mellitus .</brief_summary>
	<brief_title>Investigate Effect AZD1656 Pharmacokinetics Sitagliptin Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Patients confirm type 2 diabetes mellitus least 2 month treat metformin . Body mass index ≥19 ≤42 kg/m2 . Intake another investigational drug within last 30 day prior enrolment . Clinically significant illness clinically relevant trauma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Type 2 Diabetes Mellitus , Sitagliptin</keyword>
</DOC>